Nektar Therapeutics (NKTR) Revenue (2010 - 2026)
Nektar Therapeutics' quarterly Revenue came in at $10.9 million in Q1 2026, up 3.83% year-on-year from $10.5 million in Q1 2025, and down 50.19% quarter-over-quarter from $21.8 million in Q4 2025.
Nektar Therapeutics has reported Revenue for 17 years, with the latest figure at $10.9 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 3.83% year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $55.6 million (down 36.24% YoY), and the FY2025 full-year result was $55.2 million, down 43.89% from the prior year.
- Revenue for Q1 2026 stood at $10.9 million, down from $21.8 million in the prior quarter.
- The five-year high for Revenue was $29.2 million in Q4 2024, with the low at $10.5 million in Q1 2025.
- Average Revenue over 5 years is $20.4 million, with a median of $21.8 million recorded in 2025.
- Year-over-year, Revenue rose 22.15% in 2024 and slumped 52.42% in 2025.
- Tracing NKTR's Revenue over 5 years: stood at $22.0 million in 2022, then rose by 8.45% to $23.9 million in 2023, then increased by 22.15% to $29.2 million in 2024, then declined by 25.25% to $21.8 million in 2025, then sank by 50.19% to $10.9 million in 2026.
- The last three Revenue figures came in at $10.9 million (Q1 2026), $21.8 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Nektar Therapeutics | 1.60 Bn | 1.04 Bn | 3.16 Mn | 10.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.86 Mn |
| Dec 31, 2025 | 21.81 Mn |
| Sep 30, 2025 | 11.79 Mn |
| Jun 30, 2025 | 11.18 Mn |
| Mar 31, 2025 | 10.46 Mn |
| Dec 31, 2024 | 29.18 Mn |
| Sep 30, 2024 | 24.12 Mn |
| Jun 30, 2024 | 23.49 Mn |
| Mar 31, 2024 | 21.64 Mn |
| Dec 31, 2023 | 23.89 Mn |
| Sep 30, 2023 | 24.14 Mn |
| Jun 30, 2023 | 20.50 Mn |
| Mar 31, 2023 | 21.59 Mn |
| Dec 31, 2022 | 22.02 Mn |
| Sep 30, 2022 | 23.63 Mn |
| Jun 30, 2022 | 21.59 Mn |
| Mar 31, 2022 | 24.82 Mn |
| Dec 31, 2021 | 25.01 Mn |
| Sep 30, 2021 | 24.92 Mn |
| Jun 30, 2021 | 28.33 Mn |
| Mar 31, 2021 | 23.65 Mn |
| Dec 31, 2020 | 23.46 Mn |
| Sep 30, 2020 | 30.03 Mn |
| Jun 30, 2020 | 48.85 Mn |
| Mar 31, 2020 | 50.57 Mn |
| Dec 31, 2019 | 33.86 Mn |
| Sep 30, 2019 | 29.22 Mn |
| Jun 30, 2019 | 23.32 Mn |
| Mar 31, 2019 | 28.22 Mn |
| Dec 31, 2018 | 10.00 Mn |
| Sep 30, 2018 | 27.76 Mn |
| Jun 30, 2018 | 1.09 Bn |
| Mar 31, 2018 | 38.02 Mn |
| Dec 31, 2017 | 95.47 Mn |
| Jun 30, 2017 | 34.59 Mn |
| Mar 31, 2017 | 24.73 Mn |
| Dec 31, 2016 | 13.69 Mn |
| Sep 30, 2016 | 36.34 Mn |
| Jun 30, 2016 | 32.77 Mn |
| Mar 31, 2016 | 58.88 Mn |
| Dec 31, 2015 | 39.37 Mn |
| Sep 30, 2015 | 59.95 Mn |
| Jun 30, 2015 | 22.66 Mn |
| Mar 31, 2015 | 7.97 Mn |
| Dec 31, 2014 | 7.46 Mn |
| Sep 30, 2014 | 6.10 Mn |
| Jun 30, 2014 | 5.80 Mn |
| Mar 31, 2014 | 19.77 Mn |
| Dec 31, 2013 | 31.15 Mn |
| Sep 30, 2013 | 60.91 Mn |
| Jun 30, 2013 | 10.32 Mn |
| Mar 31, 2013 | 23.00 Mn |
| Dec 31, 2012 | 21.15 Mn |
| Sep 30, 2012 | 18.41 Mn |
| Jun 30, 2012 | 23.68 Mn |
| Mar 31, 2012 | 6.95 Mn |
| Dec 31, 2011 | 15.78 Mn |
| Sep 30, 2011 | 27.07 Mn |
| Jun 30, 2011 | 17.33 Mn |
| Mar 31, 2011 | 11.30 Mn |
| Dec 31, 2010 | 10.70 Mn |
| Sep 30, 2010 | 37.93 Mn |
| Jun 30, 2010 | 42.56 Mn |
| Mar 31, 2010 | 33.24 Mn |